Nationally Recognized Bladder Cancer Surgeon Dr. Robert Svatek Visits DHR Health

Translate to Spanish or other 102 languages!

DHR Health Urology Insitute physicians with Dr. Svatek during visit.  Left to Right: Dr. Henry Ruiz, Medical Director at DHR Health Urology Insitute, Dr. Robert Svatek, Chair of Urology at UTHSCSA, Dr. Gustavo Villegas, Dr. Maria Rodriguez, and Dr. Gaudencio Olguin.

Mega Doctor News

- Advertisement -

Edinburg, TX – Dr. Robert Svatek, the Chair of Urology at UT Science Center at San Antonio (UTHSCSA) and one of the top five highest volume bladder cancer surgeons in the United States, visited DHR Health and DHR Health Institute for Research and Development to discuss collaborative efforts that will continue to enhance the ongoing partnership of advancing clinical care and research benefiting Rio Grande Valley residents.

“Dr. Robert Svatek is a nationally recognized urologic surgeon-scientist with clinical expertise in early and late phase clinical trials and urologic cancers” said Dr. Henry Ruiz, Medical Director at DHR Health Urology Institute. “Many areas of common clinical and research interests were discussed and we look forward to continuing to work with Dr. Svatek and his team at UTHSCSA to provide the highest level of care to members of our community”.

DHR Health has endowed a Distinguished Chair in Urology at UTHSCSA. The primary objective of this endowment is to create a closer and more productive partnership between the institutions, which would benefit the Rio Grande Valley community. American Cancer Society has projected that over 248,000 patients will be diagnosed with prostate cancer in 2021 and more than 34,000 will have a fatal outcome. In addition, according to the Prostate Cancer Foundation, prostate cancer is the most commonly diagnosed cancer among Hispanic/Latino men in the United States.  

- Advertisement -

“Bladder cancer is also a serious clinical challenge in the Rio Grande Valley” said Dr. Sohail Rao, president and chief executive officer at DHR Health Institute for Research and Development.   “American Cancer Society has predicted that more than 83,700 patients will be diagnosed with bladder cancer in 2021 with a very high incidence (>20%) of fatal outcome.  Given Dr. Svatek’s interest in developing innovative strategies to treat bladder cancer, our goal is to work closely with his team at UTHSCSA to partner in these innovative clinical studies”.

For more information on research studies and collaborations, please contact Dr. Sohail Rao, president and chief executive officer at DHR Health Institute for Research and Development at (956) 362-2387 or visit www.dhrresearch.org.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

VIDA Secures $300,000 to Boost Evidence-Based Mental Health Support for Students

Valley Initiative for Development and Advancement (VIDA) has been awarded a $300,000, two-year grant from Methodist Healthcare Ministries of South Texas, Inc. to launch an innovative initiative that integrates evidence-based mental health support into workforce development, strengthening student persistence and expanding access to care for underserved communities across the Rio Grande Valley.

DHR Health Offers Advanced, Comprehensive Care for Scoliosis Patients–Early Detection is Key!

In recognition of “National Scoliosis Awareness Month” in June, DHR Health is reminding the community that comprehensive scoliosis care is available close to home through its Scoliosis Rehabilitation Clinic and Orthopedic Spine Center of Excellence.

Teaming Up to Deliver Blankets and Comfort to Cancer Patients at DHR Health

Bert Ogden Subaru, in partnership with the Blood Cancer United, recently brought comfort and encouragement to patients receiving care at DHR Health’s Oncology Institute by presenting blankets and heart-shaped pillows to individuals courageously battling cancer.

Mayo Clinic Researchers Crack Key Code in Cancer Immune Response

Researchers at Mayo Clinic have uncovered a previously hidden step in how the immune system prepares to fight cancer, a discovery that could help scientists develop more effective and longer-lasting cancer immunotherapies.
- Advertisement -